From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Indoleamine-2,3-dioxygenase or indolamine-2,3-dioxygenase or IDO is an enzyme involved in the human body's metabolism of the essential amino acid tryptophan.[1][2]

The IDO enzyme degrades (converts) tryptophan into kynurenine, and this process is strongly linked to the IDO1 and IDO2 genes.[1][3]

Notable studies and publications[edit | edit source]

  • 2019, The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS[2] (Full text)

Learn more[edit | edit source]

  • 2020, IDO and Kynurenine Metabolites in Peripheral and CNS Disorders (Full text)
  • 2018, Indoleamine 2, 3-dioxygenase regulation of immune response (Review)[4] (Full text)

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 Bilir, Cemil; Sarisozen, Can (July 1, 2017). "Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?". Journal of Oncological Sciences. 3 (2): 52–56. doi:10.1016/j.jons.2017.04.001. ISSN 2452-3364.
  2. 2.0 2.1 Phair, RobertD.; Davis, Ronald W.; Kashi, Alex A. (2019). "The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS". Diagnostics. 9 (3): 82. doi:10.3390/diagnostics9030082.
  3. National Center for Biotechnology Information (March 22, 2020). "IDO1 indoleamine 2,3-dioxygenase 1 [Homo sapiens (human)] - Gene - NCBI". Retrieved May 1, 2020.